ArticleTranslational cancer research2026
Multiomics study on the tertiary lymphatic structure signature of colon cancer.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From TLS architecture to functional immune niches: division of labor among CAFs, HEVs, and antigen-presenting cells in cancer immunotherapy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tertiary lymphoid structures (TLSs) are abnormal clusters of immune cells found in inflamed, infected, or cancerous tissues. These structures contain high concentrations of T cells, B cells, plasma cells, follicular helper T cells, follicular dendritic cells, germinal centers, and high endothelial venules. TLSs serve as sites favorable for immune cell infiltration and facilitate the generation of an inflammatory response against tumors. We aimed to determine whether the TLS-related signature can stratify prognosis, predict immune microenvironment characteristics, and inform treatment for patients with colon cancer. Methods: The gene expression profiles of 901 patients with colon cancer were analyzed, including 458 from The Cancer Genome Atlas (TCGA) and 443 from the Gene Expression Omnibus (GEO). TLS patterns were assessed in all patients. TLS signature genes (TSGs) risk scores were constructed to quantify the TLS patterns of individuals via the Cox regression model and the least absolute shrinkage and selection operator (LASSO) algorithm, and their correlation with immune checkpoint and cell invasion characteristics of the tumor microenvironment (TME) was examined. Results: In the prognostic model, TLS-related genes (TRGs), including Conclusions: TSG expression may serve as a novel biomarker and has the potential to assess the infiltration of immune cells in the TME of patients with colon cancer. This evaluation can aid in determining prognosis and providing guidance for clinical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.